Response to methotrexate in a chronic inflammatory demyelinating polyradiculoneuropathy patient.
We report a patient with chronic inflammatory demyelinating polyradiculoneuropathy and progressive resistance to standard treatment who showed a striking response to methotrexate, 20 mg/week. The improvement, which started 5 months after initiation of therapy, was consistent and permanent. It allowed the previously wheelchair-dependent patient to achieve pharmacological remission. The 2-year follow-up of this case further illustrates the role that methotrexate may play as a treatment option for CIDP patients.
Díaz-Manera
Jordi
J
Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Avenue Sant Antoni Maria Claret 167, Barcelona 08025, Spain.
Rojas-García
Ricard
R
Gallardo
Eduard
E
Illa
Isabel
I
D004185:Disability Evaluation; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D009431:Neural Conduction / Q000187:drug effects / Q000502:physiology; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D008727:Methotrexate